Synopsis
0
VMF
0
Australia
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 4-((4-chlorophenyl)methyl)-2- (hexahydro-1-methyl-1h-azepin-4-yl)-1(2h)- Phthalazinone Hcl
2. 4-(p-chlorobenzyl)-2-(n-methylperhydroazepinyl-(4))-1-(2h)-phthalazinone
3. A 5610
4. A-5610
5. Afluon
6. Allergodil
7. Astelin
8. Azelastine
9. Azeptin
10. Corifina
11. Loxin
12. Optilast
13. Optivar
14. Rhinolast
15. Vividrin Akut Azelastin
1. Azelastine Hcl
2. 79307-93-0
3. Optivar
4. Astelin
5. Allergodil
6. Rhinolast
7. Astepro
8. Azeptin
9. Azelastine (hydrochloride)
10. 37932-96-0
11. W-2979m
12. 4-(4-chlorobenzyl)-2-(1-methylazepan-4-yl)phthalazin-1(2h)-one Hydrochloride
13. A-5610
14. E-0659
15. Optilast
16. 4-[(4-chlorophenyl)methyl]-2-(1-methylazepan-4-yl)phthalazin-1-one;hydrochloride
17. Chebi:2951
18. 0l591qr10i
19. 4-(p-chlorobenzyl)-2-(hexahydro-1-methyl-1h-azepin-4-yl)-1(2h)-phthalazinone Monohydrochloride
20. Ncgc00095173-01
21. Dsstox_cid_25945
22. Dsstox_rid_81243
23. Dsstox_gsid_45945
24. 1(2h)-phthalazinone, 4-((4-chlorophenyl)methyl)-2-(hexahydro-1-methyl-1h-azepin-4-yl)-, Monohydrochloride
25. 4-[(4-chlorophenyl)methyl]-2-(hexahydro-1-methyl-1h-azepin-4-yl)phthalazin-1(2h)-one Hydrochloride
26. Corifina
27. Optilas
28. (r)-azelastine Hcl
29. (s)-azelastine Hcl
30. 4-((4-chlorophenyl)methyl)-2-(hexahydro-1-methyl-1h-azepin-4-yl)phthalazin-1(2h)-one Hydrochloride
31. Smr000469183
32. Cas-79307-93-0
33. Radethazin
34. Zalastine
35. Azep
36. Sr-01000762975
37. A 5610
38. Astelin (tn)
39. Einecs 253-720-4
40. Azelastine Hydrochloride [usan:jan]
41. Mfcd00242783
42. Astepro Allergy
43. Cpd000469183
44. Schembl36770
45. Mls001401427
46. Mls006010756
47. Spectrum1505340
48. Unii-0l591qr10i
49. Azelastine Hydrochloride- Bio-x
50. Chembl1200809
51. Dtxsid2045945
52. Azelastine Hydrochloride (astelin)
53. Bcpp000358
54. Hms1922f04
55. Pharmakon1600-01505340
56. Bcp23404
57. Hy-b0462
58. Tox21_111469
59. Azelastine Hydrochloride [mi]
60. Ccg-40046
61. Nsc758971
62. Azelastine Hydrochloride (jp17/usp)
63. Azelastine Hydrochloride [jan]
64. Akos015895420
65. Tox21_111469_1
66. Ac-5498
67. Azelastine Hydrochloride [usan]
68. Bcp9000369
69. Ccg-100841
70. Nc00091
71. W- 979m
72. Azelastine Hydrochloride [mart.]
73. Azelastine Hydrochloride [vandf]
74. Azelastine Hydrochloride [usp-rs]
75. Azelastine Hydrochloride [who-dd]
76. Ncgc00095173-02
77. Ncgc00177979-05
78. Allergodil Pound>>azelastine Hydrochloride
79. As-14079
80. Ba164232
81. Azelastine Hydrochloride, >=98% (hplc)
82. Bcp0726000233
83. Ft-0662380
84. Ft-0662381
85. S2552
86. Sw197471-3
87. Azelastine Hydrochloride [orange Book]
88. Azelastine Hydrochloride [ep Monograph]
89. Azelastine Hydrochloride [usp Monograph]
90. C76537
91. D00659
92. Dymista Component Azelastine Hydrochloride
93. 307a930
94. Azelastine Hydrochloride Component Of Dymista
95. Sr-01000762975-4
96. Q27105897
97. Azelastine Hydrochloride 1.0 Mg/ml In Methanol (as Free Base)
98. 4-(4-chlorobenzyl)-2-(1-methylazepan-4-yl)-1-phthalazinone Hydrochloride
99. Azelastine Hydrochloride, European Pharmacopoeia (ep) Reference Standard
100. 4-(4-chlorobenzyl)-2-(1-methylazepan-4-yl)phthalazin-1(2h)-onehydrochloride
101. 4-[(4-chlorophenyl)methyl]-2-(1-methyl-4-azepanyl)phthalazin-1-one Hydrochloride
102. Azelastine Hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
103. Azelastine Hydrochloride, United States Pharmacopeia (usp) Reference Standard
Molecular Weight | 418.4 g/mol |
---|---|
Molecular Formula | C22H25Cl2N3O |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 3 |
Rotatable Bond Count | 3 |
Exact Mass | 417.1374678 g/mol |
Monoisotopic Mass | 417.1374678 g/mol |
Topological Polar Surface Area | 35.9 Ų |
Heavy Atom Count | 28 |
Formal Charge | 0 |
Complexity | 558 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 8 | |
---|---|
Drug Name | Astelin |
PubMed Health | Azelastine (Into the nose) |
Drug Classes | Nasal Agent |
Drug Label | Astelin (azelastine hydrochloride) Nasal Spray, 137 micrograms (mcg), is an antihistamine formulated as a metered-spray solution for intranasal administration. Azelastine hydrochloride occurs as a white, almost odorless, crystalline powder with a b... |
Active Ingredient | Azelastine hydrochloride |
Dosage Form | Spray, metered |
Route | Nasal |
Strength | eq 0.125mg base/spray |
Market Status | Prescription |
Company | Meda Pharms |
2 of 8 | |
---|---|
Drug Name | Astepro |
Drug Label | ASTEPRO (azelastine hydrochloride) Nasal Spray 0.1%, 137 micrograms (mcg), is an antihistamine formulated as a metered-spray solution for intranasal administration. ASTEPRO (azelastine hydrochloride) Nasal Spray 0.15%, 205.5 micrograms (mcg), is form... |
Active Ingredient | Azelastine hydrochloride |
Dosage Form | Spray, metered |
Route | Nasal |
Strength | eq 0.1876mg base/spray |
Market Status | Prescription |
Company | Meda Pharms |
3 of 8 | |
---|---|
Drug Name | Azelastine hydrochloride |
Drug Label | ASTEPRO (azelastine hydrochloride) Nasal Spray 0.1%, 137 micrograms (mcg), is an antihistamine formulated as a metered-spray solution for intranasal administration. ASTEPRO (azelastine hydrochloride) Nasal Spray 0.15%, 205.5 micrograms (mcg), is form... |
Active Ingredient | Azelastine hydrochloride |
Dosage Form | Solution/drops; Spray, metered |
Route | Nasal; Ophthalmic |
Strength | 0.05%; eq 0.125mg base/spray; eq 0.1876mg base/spray |
Market Status | Prescription |
Company | Alcon Pharma; Apotex; Sun Pharma Global; Perrigo Israel |
4 of 8 | |
---|---|
Drug Name | Optivar |
PubMed Health | Azelastine |
Drug Classes | Nasal Agent, Ophthalmologic Agent |
Drug Label | OPTIVAR (azelastine hydrochloride ophthalmic solution), 0.05% is a sterile ophthalmic solution containing azelastine hydrochloride, a relatively selective H1-receptor antagonist for topical administration to the eyes. Azelastine hydrochloride is a... |
Active Ingredient | Azelastine hydrochloride |
Dosage Form | Solution/drops |
Route | Ophthalmic |
Strength | 0.05% |
Market Status | Prescription |
Company | Meda Pharms |
5 of 8 | |
---|---|
Drug Name | Astelin |
PubMed Health | Azelastine (Into the nose) |
Drug Classes | Nasal Agent |
Drug Label | Astelin (azelastine hydrochloride) Nasal Spray, 137 micrograms (mcg), is an antihistamine formulated as a metered-spray solution for intranasal administration. Azelastine hydrochloride occurs as a white, almost odorless, crystalline powder with a b... |
Active Ingredient | Azelastine hydrochloride |
Dosage Form | Spray, metered |
Route | Nasal |
Strength | eq 0.125mg base/spray |
Market Status | Prescription |
Company | Meda Pharms |
6 of 8 | |
---|---|
Drug Name | Astepro |
Drug Label | ASTEPRO (azelastine hydrochloride) Nasal Spray 0.1%, 137 micrograms (mcg), is an antihistamine formulated as a metered-spray solution for intranasal administration. ASTEPRO (azelastine hydrochloride) Nasal Spray 0.15%, 205.5 micrograms (mcg), is form... |
Active Ingredient | Azelastine hydrochloride |
Dosage Form | Spray, metered |
Route | Nasal |
Strength | eq 0.1876mg base/spray |
Market Status | Prescription |
Company | Meda Pharms |
7 of 8 | |
---|---|
Drug Name | Azelastine hydrochloride |
Drug Label | ASTEPRO (azelastine hydrochloride) Nasal Spray 0.1%, 137 micrograms (mcg), is an antihistamine formulated as a metered-spray solution for intranasal administration. ASTEPRO (azelastine hydrochloride) Nasal Spray 0.15%, 205.5 micrograms (mcg), is form... |
Active Ingredient | Azelastine hydrochloride |
Dosage Form | Solution/drops; Spray, metered |
Route | Nasal; Ophthalmic |
Strength | 0.05%; eq 0.125mg base/spray; eq 0.1876mg base/spray |
Market Status | Prescription |
Company | Alcon Pharma; Apotex; Sun Pharma Global; Perrigo Israel |
8 of 8 | |
---|---|
Drug Name | Optivar |
PubMed Health | Azelastine |
Drug Classes | Nasal Agent, Ophthalmologic Agent |
Drug Label | OPTIVAR (azelastine hydrochloride ophthalmic solution), 0.05% is a sterile ophthalmic solution containing azelastine hydrochloride, a relatively selective H1-receptor antagonist for topical administration to the eyes. Azelastine hydrochloride is a... |
Active Ingredient | Azelastine hydrochloride |
Dosage Form | Solution/drops |
Route | Ophthalmic |
Strength | 0.05% |
Market Status | Prescription |
Company | Meda Pharms |
Histamine H1 Antagonists, Non-Sedating
A class of non-sedating drugs that bind to but do not activate histamine receptors (DRUG INVERSE AGONISM), thereby blocking the actions of histamine or histamine agonists. These antihistamines represent a heterogenous group of compounds with differing chemical structures, adverse effects, distribution, and metabolism. Compared to the early (first generation) antihistamines, these non-sedating antihistamines have greater receptor specificity, lower penetration of BLOOD-BRAIN BARRIER, and are less likely to cause drowsiness or psychomotor impairment. (See all compounds classified as Histamine H1 Antagonists, Non-Sedating.)
Anti-Allergic Agents
Agents that are used to treat allergic reactions. Most of these drugs act by preventing the release of inflammatory mediators or inhibiting the actions of released mediators on their target cells. (From AMA Drug Evaluations Annual, 1994, p475) (See all compounds classified as Anti-Allergic Agents.)
Bronchodilator Agents
Agents that cause an increase in the expansion of a bronchus or bronchial tubes. (See all compounds classified as Bronchodilator Agents.)
Lipoxygenase Inhibitors
Compounds that bind to and inhibit that enzymatic activity of LIPOXYGENASES. Included under this category are inhibitors that are specific for lipoxygenase subtypes and act to reduce the production of LEUKOTRIENES. (See all compounds classified as Lipoxygenase Inhibitors.)
GDUFA
DMF Review : Reviewed
Rev. Date : 2023-11-01
Pay. Date : 2023-09-22
DMF Number : 36205
Submission : 2021-10-09
Status : Active
Type : II
Certificate Number : R0-CEP 2021-124 - Rev 00
Issue Date : 2022-08-10
Type : Chemical
Substance Number : 1633
Status : Valid
Date of Issue : 2022-09-16
Valid Till : 2025-07-05
Written Confirmation Number : WC-0009
Address of the Firm :
NDC Package Code : 49076-7601
Start Marketing Date : 2019-06-17
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 15440
Submission : 2001-05-15
Status : Active
Type : II
Certificate Number : CEP 2009-333 - Rev 05
Issue Date : 2024-04-24
Type : Chemical
Substance Number : 1633
Status : Valid
NDC Package Code : 49274-1101
Start Marketing Date : 2001-05-15
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Bukwang Pharmaceutical Co., Ltd.
Registration Date : 2008-08-29
Registration Number : 20080829-44-C-224-06
Manufacturer Name : Evonik Operations GmbH
Manufacturer Address : Rodenbacher Chaussee 4 63457 Hanau, Germany
Vamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.
Tenatra connects Indian manufacturers with global buyers through active partners in Germany, Switzerland, Belgium, Spain & Turkey.
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-11-20
Pay. Date : 2013-11-14
DMF Number : 22427
Submission : 2009-01-20
Status : Active
Type : II
Certificate Number : R1-CEP 2010-010 - Rev 03
Issue Date : 2020-08-17
Type : Chemical
Substance Number : 1633
Status : Valid
NDC Package Code : 57572-0713
Start Marketing Date : 2007-09-28
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-09-10
Pay. Date : 2013-08-29
DMF Number : 18398
Submission : 2005-06-01
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 36748
Submission : 2022-03-16
Status : Active
Type : II
NDC Package Code : 68578-0017
Start Marketing Date : 2021-12-15
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 24317
Submission : 2010-09-28
Status : Active
Type : II
Registrant Name : Korea United Pharmaceutical Co., Ltd.
Registration Date : 2005-09-30
Registration Number : 20050930-44-C-150-04
Manufacturer Name : Korea United Pharmaceuticals
Manufacturer Address : 107 Gongdan-ro, Yeonsu-myeon, Sejong Special Self-Governing City_x000D_
GDUFA
DMF Review : Reviewed
Rev. Date : 2015-02-25
Pay. Date : 2015-02-18
DMF Number : 15361
Submission : 2001-03-29
Status : Active
Type : II
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
Patent Expiration Date : 2028-06-04
US Patent Number : 8071073
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 213872
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2028-06-04
Patent Expiration Date : 2025-11-22
US Patent Number : 8518919
Drug Substance Claim :
Drug Product Claim :
Application Number : 213872
Patent Use Code : U-3166
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2025-11-22
Patent Expiration Date : 2025-11-22
US Patent Number : 8518919
Drug Substance Claim :
Drug Product Claim :
Application Number : 213872
Patent Use Code : U-3166
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2025-11-22
Patent Expiration Date : 2025-11-22
US Patent Number : 9919050
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 213872
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2025-11-22
Patent Expiration Date : 2026-08-24
AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE
US Patent Number : 8168620*PED
Drug Substance Claim :
Drug Product Claim :
Application Number : 202236
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2026-08-24
Patent Expiration Date : 2026-02-24
AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE
US Patent Number : 8168620
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 202236
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2026-02-24
Patent Expiration Date : 2028-06-04
US Patent Number : 8071073
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 22203
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2028-06-04
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Patent Expiration Date : 2025-11-22
US Patent Number : 9919050
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 22203
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2025-11-22
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Patent Expiration Date : 2028-06-04
US Patent Number : 8071073
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 22203
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2028-06-04
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Patent Expiration Date : 2025-11-22
US Patent Number : 8518919
Drug Substance Claim :
Drug Product Claim :
Application Number : 22203
Patent Use Code : U-1430
Delist Requested :
Patent Use Description : TREATMENT OF ALLERGIC ...
Patent Expiration Date : 2025-11-22
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
88
PharmaCompass offers a list of Azelastine Hydrochloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Azelastine Hydrochloride manufacturer or Azelastine Hydrochloride supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Azelastine Hydrochloride manufacturer or Azelastine Hydrochloride supplier.
PharmaCompass also assists you with knowing the Azelastine Hydrochloride API Price utilized in the formulation of products. Azelastine Hydrochloride API Price is not always fixed or binding as the Azelastine Hydrochloride Price is obtained through a variety of data sources. The Azelastine Hydrochloride Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Loxin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Loxin, including repackagers and relabelers. The FDA regulates Loxin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Loxin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Loxin manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Loxin supplier is an individual or a company that provides Loxin active pharmaceutical ingredient (API) or Loxin finished formulations upon request. The Loxin suppliers may include Loxin API manufacturers, exporters, distributors and traders.
click here to find a list of Loxin suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Loxin DMF (Drug Master File) is a document detailing the whole manufacturing process of Loxin active pharmaceutical ingredient (API) in detail. Different forms of Loxin DMFs exist exist since differing nations have different regulations, such as Loxin USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Loxin DMF submitted to regulatory agencies in the US is known as a USDMF. Loxin USDMF includes data on Loxin's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Loxin USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Loxin suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Loxin Drug Master File in Japan (Loxin JDMF) empowers Loxin API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Loxin JDMF during the approval evaluation for pharmaceutical products. At the time of Loxin JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Loxin suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Loxin Drug Master File in Korea (Loxin KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Loxin. The MFDS reviews the Loxin KDMF as part of the drug registration process and uses the information provided in the Loxin KDMF to evaluate the safety and efficacy of the drug.
After submitting a Loxin KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Loxin API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Loxin suppliers with KDMF on PharmaCompass.
A Loxin CEP of the European Pharmacopoeia monograph is often referred to as a Loxin Certificate of Suitability (COS). The purpose of a Loxin CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Loxin EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Loxin to their clients by showing that a Loxin CEP has been issued for it. The manufacturer submits a Loxin CEP (COS) as part of the market authorization procedure, and it takes on the role of a Loxin CEP holder for the record. Additionally, the data presented in the Loxin CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Loxin DMF.
A Loxin CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Loxin CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Loxin suppliers with CEP (COS) on PharmaCompass.
A Loxin written confirmation (Loxin WC) is an official document issued by a regulatory agency to a Loxin manufacturer, verifying that the manufacturing facility of a Loxin active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Loxin APIs or Loxin finished pharmaceutical products to another nation, regulatory agencies frequently require a Loxin WC (written confirmation) as part of the regulatory process.
click here to find a list of Loxin suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Loxin as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Loxin API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Loxin as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Loxin and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Loxin NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Loxin suppliers with NDC on PharmaCompass.
Loxin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Loxin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Loxin GMP manufacturer or Loxin GMP API supplier for your needs.
A Loxin CoA (Certificate of Analysis) is a formal document that attests to Loxin's compliance with Loxin specifications and serves as a tool for batch-level quality control.
Loxin CoA mostly includes findings from lab analyses of a specific batch. For each Loxin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Loxin may be tested according to a variety of international standards, such as European Pharmacopoeia (Loxin EP), Loxin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Loxin USP).